Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / *W EXP 99/99/999
-
Total 13F shares
-
1,884,490
-
Share change
-
-352,417
-
Total reported value
-
$3,937,579
-
Price per share
-
$2.09
-
Number of holders
-
18
-
Value change
-
-$678,321
-
Number of buys
-
3
-
Number of sells
-
5
Institutional Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q2 2023
As of 30 Jun 2023,
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,884,490 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., HIGHBRIDGE CAPITAL MANAGEMENT LLC, RA CAPITAL MANAGEMENT, L.P., Ensign Peak Advisors, Inc, Bain Capital Life Sciences Investors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Affinity Asset Advisors, LLC, Walleye Capital LLC, Westchester Capital Management, LLC, and HRT FINANCIAL LP.
This page lists
18
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.